Ganoderma lucidum as a Functional Bioactive Candidate for Glycemic Regulation: Mechanisms, Preclinical Evidence, and Clinical Translation
Metabolites · 15.05.2026 · 16 (5) · 334
DOI: 10.3390/metabo16050334 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 15.05.2026. Verfasst von Bogdan Florea und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Life Sciences "King Mihai I" from Timisoara, 300645 Timisoara, Romania. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is a major global health challenge that has intensified interest in multi-target nutraceuticals with potential adjunctive benefits. Ganoderma lucidum (Lingzhi/Reishi) is a medicinal mushroom traditionally used in East Asia and is increasingly investigated for its role in glycemic regulation and metabolic disturbances. This review critically synthesizes current evidence on its hypoglycemic effects, focusing on bioactive compounds, molecular mechanisms, and translational limitations. Unlike broader reviews on Ganoderma bioactivity and health-related benefits, this review specifically evaluates the alignment between taxonomic authentication, chemical standardization, preclinical mechanisms, and human clinical evidence in the context of glycemic regulation. This narrative review was based on a targeted literature search conducted in PubMed/MEDLINE, Web of Science, and Scopus for studies published up to October 2025, supplemented by Google Scholar. The included studies comprised in vitro experiments, in vivo animal models, and human clinical trials evaluating glycemic and metabolic outcomes of Ganoderma preparations. In vitro and animal studies indicate that polysaccharides, including β-(1→3)/(1→6)-glucans and proteoglycans such as FYGL, may improve insulin sensitivity via AMPK (AMP-activated protein kinase) and PI3K/Akt pathways, promote GLUT4 (glucose transporter type 4) translocation, suppress hepatic gluconeogenesis, protect pancreatic β-cells, and modulate gut microbiota. In enzyme assays and preclinical models, lanostane-type triterpenoids act primarily by inhibiting α-glucosidase and α-amylase, thereby potentially reducing postprandial glucose excursions. Despite consistent preclinical evidence, clinical findings remain heterogeneous, with the largest randomized controlled trial reporting no significant glycemic benefit. Overall, Ganoderma lucidum shows strong mechanistic plausibility but insufficient clinical evidence for antidiabetic efficacy. Future research should prioritize species authentication, chemical standardization, and adequately powered clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Life Sciences "King Mihai I" from Timisoara, 300645 Timisoara, Romania.
- Doctoral School "Veterinary Medicine", University of Life Sciences "King Mihai I" from Timişoara, Calea Aradului 119, 300645 Timişoara, Romania.
- Department of Infectious Diseases and Preventive Medicine, University of Life Sciences "King Mihai I" from Timisoara, 300645 Timisoara, Romania.
- Department of Pharmacy and Pharmacology, University of Life Sciences "King Mihai I" from Timisoara, 300645 Timisoara, Romania.
- Department of Parasitology, University of Life Sciences "King Mihai I" from Timisoara, 300645 Timisoara, Romania.
ORCID-Profile: Bogdan Florea, Doru Morar, Corina Marina Kracunovic, Simina Velescu, Paula Nistor, Janos Degi, Ionica Iancu, Maria-Larisa Ardelean Rusu, Romeo Teodor Cristina, Alexandra Pocinoc, Eugenia Dumitrescu
Zitieren
APA
Florea, B., Morar, D., Kracunovic, C. M., Velescu, S., Iorgoni, V., Nistor, P., Degi, J., Iancu, I., Ardelean Rusu, M. L., Cristina, R. T., Pocinoc, A., & Dumitrescu, E. (2026). Ganoderma lucidum as a Functional Bioactive Candidate for Glycemic Regulation: Mechanisms, Preclinical Evidence, and Clinical Translation. Metabolites, 16(5), 334. https://doi.org/10.3390/metabo16050334
Vancouver
Florea B, Morar D, Kracunovic CM, Velescu S, Iorgoni V, Nistor P, et al. Ganoderma lucidum as a Functional Bioactive Candidate for Glycemic Regulation: Mechanisms, Preclinical Evidence, and Clinical Translation. Metabolites. 2026;16(5):334. doi:10.3390/metabo16050334
BibTeX
@article{Florea2026,
author = {Florea, Bogdan and Morar, Doru and Kracunovic, Corina Marina and Velescu, Simina and Iorgoni, Vlad and Nistor, Paula and Degi, Janos and Iancu, Ionica and Ardelean Rusu, Maria-Larisa and Cristina, Romeo Teodor and Pocinoc, Alexandra and Dumitrescu, Eugenia},
title = {Ganoderma lucidum as a Functional Bioactive Candidate for Glycemic Regulation: Mechanisms, Preclinical Evidence, and Clinical Translation},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {5},
pages = {334},
doi = {10.3390/metabo16050334}
}
EUVIMED